A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.

[1]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[2]  D. Demicco,et al.  Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. , 2015, Journal of the American College of Cardiology.

[3]  Ž. Reiner.  Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease? , 2015, Cardiology.

[4]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[5]  Cholesterol Treatment Trialists.  Effi cacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015 .

[6]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[7]  J. Pedro-Botet,et al.  Dislipemia aterogénica: prevalencia y control en las unidades de lípidos , 2014 .

[8]  R. D'Agostino,et al.  Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. , 2014, American heart journal.

[9]  J. Banegas,et al.  Atherogenic dyslipidemia: prevalence and management in lipid clinics. , 2014 .

[10]  J. Tomassini,et al.  Combination therapy in dyslipidemia: where are we now? , 2014, Atherosclerosis.

[11]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[12]  A. Kontush.  HDL-mediated mechanisms of protection in cardiovascular disease. , 2014, Cardiovascular research.

[13]  V. Gebski,et al.  HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes , 2014, Diabetes Care.

[14]  H. Hauner,et al.  Costs of Diabetes Mellitus (CoDiM) in Germany, Direct Per-capita Costs of Managing Hyperglycaemia and Diabetes Complications in 2010 Compared to 2001 , 2014, Experimental and Clinical Endocrinology & Diabetes (Barth).

[15]  B. G. Brown,et al.  Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. , 2014, The American journal of cardiology.

[16]  Á. Chamorro,et al.  Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients , 2014, Stroke.

[17]  T. Lüscher,et al.  The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. , 2014, European heart journal.

[18]  M. Kostapanos,et al.  High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. , 2014, World journal of experimental medicine.

[19]  A. Gotto,et al.  Residual macrovascular risk in 2013: what have we learned? , 2014, Cardiovascular Diabetology.

[20]  F. Sacks,et al.  Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries , 2013, Circulation.

[21]  S. Grundy,et al.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. , 2014, Journal of clinical lipidology.

[22]  G. De Backer,et al.  Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. , 2013, Atherosclerosis.

[23]  A. Keech,et al.  Fenofibrate and renal disease: clinical effects in diabetes , 2013 .

[24]  M. Puato,et al.  Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for non-HDL-C. , 2013, Atherosclerosis.

[25]  Ž. Reiner.  Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[26]  R. D'Agostino,et al.  High-density lipoproteins: a consensus statement from the National Lipid Association. , 2013, Journal of clinical lipidology.

[27]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[28]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[29]  H. Ginsberg,et al.  Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial , 2013, Diabetes Care.

[30]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[31]  P. Ridker,et al.  Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. , 2012, JAMA.

[32]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[33]  M. Woodward,et al.  Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy , 2012, Diabetes Care.

[34]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[35]  T. Craven,et al.  Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants , 2012, Diabetes Care.

[36]  A. Zwinderman,et al.  Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.

[37]  P. O’Connor,et al.  Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience , 2012, Diabetologia.

[38]  E. Bonora,et al.  Triglyceride-high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. , 2012, Metabolism: clinical and experimental.

[39]  S. Benemei,et al.  Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. , 2012, Clinical therapeutics.

[40]  J. Caro,et al.  Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus , 2012, PharmacoEconomics.

[41]  J. Breslow,et al.  How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? , 2012, Current Atherosclerosis Reports.

[42]  Lawrence A Leiter,et al.  Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[43]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[44]  G. Keating,et al.  Fenofibrate , 2011, Drugs.

[45]  W. März,et al.  "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. , 2011, Current vascular pharmacology.

[46]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[47]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[48]  P. Valensi,et al.  Lipids, lipid-lowering therapy and diabetes complications. , 2011, Diabetes & metabolism.

[49]  M. Clearfield.  Combination Lipid Therapy in Type 2 Diabetes , 2011, Current atherosclerosis reports.

[50]  Jennifer Y. Liu,et al.  Triglycerides and Amputation Risk in PatientsWith Diabetes Ten-year follow-up in the DISTANCE study , 2011 .

[51]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[52]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[53]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[54]  Rayaz A. Malik,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[55]  Vincent J Carey,et al.  Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. , 2010, The American journal of cardiology.

[56]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[57]  Paul Schoenhagen,et al.  Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. , 2010, Journal of the American College of Cardiology.

[58]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[59]  Ž. Reiner.  Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & Clinical Pharmacology.

[60]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[61]  R. Rosenson,et al.  Residual microvascular risk in diabetes: unmet needs and future directions , 2010, Nature Reviews Endocrinology.

[62]  B. Okopień,et al.  Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. , 2010, Pharmacological reports : PR.

[63]  Paul T. Williams,et al.  Ion Mobility Analysis of Lipoprotein Subfractions Identifies Three Independent Axes of Cardiovascular Risk , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[64]  S. Grundy,et al.  Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. , 2009, The American journal of cardiology.

[65]  E. Feldman,et al.  Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy , 2009, Diabetes.

[66]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[67]  Marja,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2009 .

[68]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[69]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[70]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.

[71]  J. Liao.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[72]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[73]  Cholesterol Treatment Trialists' Collaborators.  Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[74]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[75]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[76]  W. Howard.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[77]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[78]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[79]  S. Grundy,et al.  Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.

[80]  T. Fahey,et al.  Interventions to improve adherence to lipid lowering medication. , 2004, The Cochrane database of systematic reviews.

[81]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[82]  B. Okopień,et al.  Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. , 2004, International journal of clinical pharmacology and therapeutics.

[83]  L. Blonde,et al.  Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin , 2003, Diabetes, obesity & metabolism.

[84]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[85]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[86]  P. Scuffham,et al.  The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S. , 2003 .

[87]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[88]  P. Scuffham,et al.  The health care costs of diabetic peripheral neuropathy in the US. , 2003, Diabetes care.

[89]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[90]  C. Ballantyne.  Low-density lipoproteins and risk for coronary artery disease. , 1998, The American journal of cardiology.

[91]  J. Hokanson,et al.  Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[92]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[93]  B. Nordestgaard,et al.  Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[94]  D. Salem,et al.  Prevalence of risk factors in men with premature coronary artery disease. , 1991, The American journal of cardiology.

[95]  R. Wootton,et al.  Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[96]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[97]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.